Melan-A / MART-1Catalog number: ME110
The antibody A103 is suitable for the detection of Melan-A antigen (syn. MART-1) in cells of melanoic origin. The antibody will label 80-90% of metastasing malign melanoma (1, 6). Melan-A-negative melanoma usually are of the spindle cell or desmoblastic type. The antibody also reacts positive with angiomyolipoma (4) and steroid hormone producing cells of the adrenal gland, ovary, testis and especially with carcinoma of these organs. Melan-A is a melanoma specific antigen, which is detected by cytotoxic T-cells. It is exprimed by benign naevi and melanoma cells. 20-22 kDA Melan-A protein, no cross-reactivity to MAGE-1 and Tyrosinase.
Immunogen: Recombinant Melan-A protein
Antibody solution in stabilizing phosphate buffer pH 7.3. Contains 0.09 % sodium azide**. The volume is sufficient for at least 100 immunohistochemical tests (100 µl working solution / test). Use appropriate antibody diluent e.g. BIOLOGO Art .No. PU002.
Purification Method: Antibody solution in stabilizing phosphate buffer pH 7.3. Contains 0.09 % sodium azide**. The volume is sufficient for at least 100 immunohistochemical tests (100 µl working solution / test). Use appropriate antibody diluent e.g. BIOLOGO Art .No. PU002.
Secondary Reagents: We recommend the use of BIOLOGO's Universal Staining System DAB (Art. No. DA005) or AEC (Art.-No. AE005).
Species Reactivity: Human
Incubation Time: 60 min at RT
Working Concentration: (liquid conc.) 1:10 - 1:20
Pre-Treatment: Heat pre-treatment of formalin fixed material with Unmasking Fluid G (Art.-No. DE007) is recommended.
Positive Control: Melanoma
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Exalpha Biologicals accepts no liability for any inaccuracies or omissions in this information.
1. Jungbluth AA, Busam KJ, Gerald WL, Stockert E, Coplan KA, Iversen K, MacGregor DP, Old LJ, Chen YT. A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues. Am J Surg Pathol. 1998 May;22(5):595-602. 2.Berset M, Cerottini JP, Guggisberg D, Romero P, Burri F, Rimoldi D, Panizzon RG. Expression of Melan-A/MART-1 antigen as a prognostic factor in primary cutaneous melanoma. Int J Cancer. 2001 Jan 20;95(1):73-7. 3. Florell SR, Zone JJ, Gerwels JW. Basal cell carcinomas are populated by melanocytes and Langerhan's cells. Am J Dermatopathol. 2001 Feb;23(1):24-8. 4. Zavala-Pompa A, Folpe AL, Jimenez RE, Lim SD, Cohen C, Eble JN, Amin MB. Immunohistochemical study of microphthalmia transcription factor and tyrosinase in angiomyolipoma of the kidney, renal cell carcinoma, and renal and retroperitoneal sarcomas: comparative evaluation with traditional diagnostic markers. Am J Surg Pathol. 2001 Jan;25(1):65-70. 5. Schmuth M, Spotl L, Zelger B, Weinlich G, Zelger B. Clear cells in acral melanoma. Eur J Dermatol. 2001 Jan-Feb;11(1):21-4.
Safety Datasheet(s) for this product: